# Medical AI Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medical-ai-co

- Industry: Healthcare IT
- Headquarters: Seoul, South Korea
- Website: www.medicalai.com/
- Total disclosed funding: $5.9M
- Latest round: Series B (Jul 9, 2025)
- Investors on record: 4

## About

Founded in 2019 and headquartered in Seoul, South Korea, Medical AI Co., Ltd. focuses on developing AI-driven solutions for analyzing electrocardiogram (ECG) data. The current CEO is Junmyung Kwon. In February 2026, Medical AI Co., Ltd. raised an undisclosed amount of venture funding from new investor Naver.

Medical AI Co., Ltd. specializes in advanced medical technology solutions, particularly in the realm of artificial intelligence for healthcare. Their core offerings include a software platform that utilizes AI to analyze electrocardiogram (ECG) data, providing interpretations that indicate the likelihood of specific diseases through risk assessments. This platform facilitates remote consultations, enabling medical professionals to share ECGs and collaborate on interpretations. The company also offers the U-healthcare gateway software, which allows users to upload 1-lead ECG data collected via smartwatches or portable ECG devices. The target end users for these products include healthcare providers, hospitals, and clinics, primarily in South Korea and other regions seeking innovative healthcare technologies.

The revenue model for Medical AI is structured around B2B transactions with healthcare institutions, which may involve software subscriptions and partnerships for ongoing access to their AI-driven ECG analysis tools. Clients, including hospitals and medical facilities, subscribe to the platform for continuous usage and benefit from regular updates and support. The flagship product offerings, such as AiTiA ECG Center and AiTiA ECG Triage, are included in these subscription agreements. In addition to direct sales, the company may engage in partnerships with medical device manufacturers and healthcare networks to expand its reach and service capabilities, solidifying its position in the healthcare technology market.

The company will use the February 2026 funding for collaborative initiatives with Naver, aiming to further develop the healthcare ecosystem.

## Funding rounds

- Series B, Jul 9, 2025, $5.9M — IMM Investment, Daewoong Pharmaceutical
- Series A, Jul 31, 2023 — Widwin Investment, New Paradigm Investment

## Investors

- Widwin Investment (https://capitalatlas.ai/funds/widwin-investment) — Series A
- New Paradigm Investment (https://capitalatlas.ai/funds/new-paradigm-investment) — Series A
- IMM Investment (https://capitalatlas.ai/funds/imm-investment) — Series B
- Daewoong Pharmaceutical — Series B